BrightPath Biotherapeutics Co., Ltd. (TYO:4594)

Japan flag Japan · Delayed Price · Currency is JPY
40.00
+1.00 (2.56%)
Jun 6, 2025, 3:30 PM JST
-35.48%
Market Cap 3.53B
Revenue (ttm) 262.00M
Net Income (ttm) -1.87B
Shares Out 90.49M
EPS (ttm) -44.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 121,500
Average Volume 351,170
Open 40.00
Previous Close 39.00
Day's Range 39.00 - 40.00
52-Week Range 32.00 - 89.00
Beta 1.25
RSI 50.62
Earnings Date May 9, 2025

About TYO:4594

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 42
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4594
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.